Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial - 16/08/18
, Claudia Zeidler, MD a, Claudia Riepe, MD a, Philipp Bruland, PhD c, Iñaki Soto-Rey, PhD c, Michael Storck, PhD c, Matthias Augustin, MD b, Svetlana Bobko, MD d, Simone Garcovich, MD e, Franz J. Legat, MD f, g, Andrey Lvov, MD d, Laurent Misery, MD PhD h, Nani Osada, PhD c, Adam Reich, MD i, j, Ekin Şavk, MD k, Esther Serra-Baldrich, MD l, Markus Streit, MD m, Jacek C. Szepietowski, MD i, Wolfgang Weger, MD f, Martin Dugas, MD c, Sonja Ständer, MD aAbstract |
Background |
Chronic pruritus is a multifactorial, challenging symptom of global relevance.
Objective |
The European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) investigation aimed to analyze the severity and humanistic burden of chronic pruritus in patients suffering from inflammatory dermatoses across Europe.
Methods |
Prospectively collected routine data on 552 patients (with atopic dermatitis, contact dermatitis, prurigo nodularis, psoriasis vulgaris, lichen planus, or mycosis fungoides [pruritus numeric rating scale score ≥3]) from 9 European centers (in Austria, France, Germany, Italy, Poland, Russia, Spain, Switzerland, and Turkey) were analyzed by univariate and multivariate variance analyses of various itch characteristics and quality of life (as measured by the Dermatology Life Quality Index and the ItchyQoL).
Results |
Duration, frequency, and intensity of pruritus (according to a numeric rating scale and visual analog scale) and related impairment of quality of life differed between European centers and dermatologic diagnoses (P < .05). The country in which the center was located had a greater impact on how patients evaluated pruritus intensity and quality of life than diagnosis did (P < .001).
Limitations |
One center per country was included.
Conclusion |
The humanistic burden of chronic pruritus in patients with inflammatory dermatoses is high. European cross-cultural factors may have a stronger influence than a specific dermatologic diagnosis on how patients rate intensity of pruritus and quality of life.
Le texte complet de cet article est disponible en PDF.Key words : care situation, humanistic burden, pruritus intensity, pruritus measurement, prurigo, quality of life
Abbreviations used : AD, CP, DLQI, NRS, QoL, VAS
Plan
| Funding sources: Supported by the European Academy of Dermatology and Venereology (European Academy of Dermatology and Venereology project No. 2014-022 to Dr Ständer). |
|
| Disclosure: Dr Augustin has served as a consultant and/or paid speaker for and/or has received research grants and/or honoraria for consulting and/or scientific lectures for and/or travel expense reimbursement from and/or has participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Almirall, Amgen, Biogen (Biogen Idec), Boehringer Ingelheim, Celgene, Centocor, Eli Lilly and Company, Galderma, Janssen-Cilag, Leo, Medac, MSD, Mundipharma, Novartis, Pfizer, Sandoz, and Xenoport. Dr Misery has served as a consultant and/or paid speaker for and/or has received research grants and/or honoraria for consulting and/or scientific lectures for and/or travel expense reimbursement from AbbVie, Amgen, Astellas, BASF, Beiersdorf, Bioderma, Celgene, Clarins, GlaxoSmithKline, Johnson & Johnson, and Pierre Fabre. Dr Reich has served as a consultant, advisory board member, and/or paid speaker for and/or has received research grants and/or honoraria for consulting and/or scientific lectures for and/or received travel expense reimbursement from and/or participated in clinical trials sponsored by Celgene, Almirall, Leo Pharma, Eli Lilly and Company, Novartis, Menlo Pharmaceuticals, Chema Rzeszow, Sun-Farm, Bioderma, and Galderma. Dr Ständer has served as a consultant, advisory board member, investigator, and/or paid speaker for and/or has received research grants and/or honoraria for consulting and/or scientific lectures for and/or received travel expense reimbursement from Dermasence, Beiersdorf, Celgene, Creabilis, Galderma, Helsinn, Kiniksa, Menlo, NeRRe Therapeutics, Novartis, Sienna, and Trevi. Dr Szepietowksi has served as a consultant, advisory board member, and/or paid speaker for and/or has received research grants and/or honoraria for consulting and/or scientific lectures for and/or received travel expense reimbursement from and/or participated in clinical trials sponsored by Leo Pharma, Celgene, Novartis, Pierre-Fabre, Menlo, AbbVie, Dignity Sciences, Sandoz, Actelion, Amgen, GlaxoSmithKline, Janssen, Merck, Regeneron, Trevi, Eli Lilly and Company, SunFarm, and Polfa Tarchomin. Dr Streit has received honoraria as an advisory board member for Novartis, Pfizer, Menlo, Celgene, and Almirall. Dr Bobko, Dr Bruland, Dr Dugas, Dr Garcovich, Dr Legat, Dr Lvov, Dr Osada, Dr Riepe, Dr Savk, Dr Serra-Baldrich, Dr Soto-Rey, Dr Steinke, Dr Storck, Dr Weger, and Dr Zeidler have no conflicts of interest to disclose. |
Vol 79 - N° 3
P. 457 - septembre 2018 Retour au numéro
Article précédent
- Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis
- Amalie Thorsti Møller Rønnstad, Anne-Sofie Halling-Overgaard, Carsten R. Hamann, Lone Skov, Alexander Egeberg, Jacob P. Thyssen
- Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index
- Peter B. Chansky, Jeannette M. Olazagasti, Rui Feng, Victoria P. Werth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?